These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 30300449

  • 1. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
    Antmen B, Karakaş Z, Yeşilipek MA, Küpesiz OA, Şaşmaz İ, Uygun V, Kurtoğlu E, Oktay G, Aydogan G, Akın M, Salcioglu Z, Vergin C, Kazancı EG, Ünal S, Çalışkan Ü, Aral YZ, Türkkan E, Meral Güneş A, Tunç B, Gümrük F, Ayhan AC, Söker M, Koç A, Oymak Y, Ertem M, Timur Ç, Yıldırmak Y, İrken G, Apak H, Biner B, Eren TG, Işık Balcı Y, Koçak Ü, Karasu G, Akkaynak D, Patıroğlu T.
    Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A.
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [Abstract] [Full Text] [Related]

  • 3. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
    Nolte F, Nückel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hofmann WK.
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
    [Abstract] [Full Text] [Related]

  • 4. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes.
    Yusuf S, Herdata HN, Edward ED, Khairunnisa K.
    F1000Res; 2023 Aug; 12():154. PubMed ID: 39233713
    [Abstract] [Full Text] [Related]

  • 5. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.
    Pinto VM, Balocco M, Quintino S, Bacigalupo L, Gianesin B, Rizzi M, Malagò R, De Franceschi L, Forni GL.
    Am J Hematol; 2018 Oct; 93(10):E338-E340. PubMed ID: 30033633
    [No Abstract] [Full Text] [Related]

  • 6. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E, Kaya B, Gadong N, Hemmaway C, Newell H, Simmons A, Whitmarsh S, Telfer P.
    Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
    [Abstract] [Full Text] [Related]

  • 7. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
    Kattamis A, Aydinok Y, Taher A.
    Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
    [Abstract] [Full Text] [Related]

  • 8. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB, Elalfy M, Taher A, Aydinok Y, Lee SH, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A.
    Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.
    Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha.
    Panigrahi M, Swain TR, Jena RK, Panigrahi A, Debta N.
    Indian J Pharmacol; 2020 Aug; 52(3):172-178. PubMed ID: 32873999
    [Abstract] [Full Text] [Related]

  • 12. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
    Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A, EPIC Study Investigators.
    Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
    [Abstract] [Full Text] [Related]

  • 13. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
    Gomber S, Jain P, Sharma S, Narang M.
    Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
    [Abstract] [Full Text] [Related]

  • 14. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
    Yesilipek MA, Karasu G, Kaya Z, Kuskonmaz BB, Uygun V, Dag I, Ozudogru O, Ertem M.
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):613-618. PubMed ID: 29155313
    [Abstract] [Full Text] [Related]

  • 15. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
    Taher AT, Wali Y, Cruz MC, Charoenkwan P, Aydinok Y, Werner O, Govindaraju S, Romen F, Viprakasit V.
    Haematologica; 2024 May 01; 109(5):1413-1425. PubMed ID: 37855069
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.
    Ann Hematol; 2013 Jan 01; 92(2):211-9. PubMed ID: 23086508
    [Abstract] [Full Text] [Related]

  • 17. A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.
    Wei Z, Yang G, Huang Y, Peng P, Long L, Long Y, Huang X, Zhou X, Lai Y, Liu R.
    Br J Haematol; 2020 Nov 01; 191(3):e81-e83. PubMed ID: 32945527
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR, Delhikumar CG, Ram Kumar G.
    Indian J Pediatr; 2021 Apr 01; 88(4):330-335. PubMed ID: 32661609
    [Abstract] [Full Text] [Related]

  • 19. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
    Aubart M, Ou P, Elie C, Canniffe C, Kutty S, Delos V, Graffigne C, de Montalembert M, Brousse V.
    J Pediatr Hematol Oncol; 2016 Oct 01; 38(7):497-502. PubMed ID: 27548334
    [Abstract] [Full Text] [Related]

  • 20. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 01; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.